论文部分内容阅读
近年来,越来越多的动物实验显示转换酶制剂可自有效地延缓糖尿病肾病DN的进展。为此,我们观测了苯那普利治疗肾脏可能的保护作用。 1 材料与方法 1.1 病人资料及观察方法:21例非胰岛素依赖型DN患者(按WHO标准诊断及分型),男11例,女10例,年龄48.7±7.4岁,病程5.7±1.2年,其中血压高者9例,肾功能不全者11例。全部病例均予口服降糖药或胰岛素使空腹血糖控制正常后,加服苯那普利(10mg/mg,1/日),连服2周,并于治疗前、血糖控制正常及苯那普利治疗2周后观察患者血压、24小时尿蛋白定量(TUP),尿白蛋白清除率(UAER)内生肌酐清除率(Ccr)。
In recent years, more and more animal experiments show that the conversion enzyme preparation can effectively delay the progression of diabetic nephropathy DN. To this end, we observed possible protective effects of benazepril on the kidneys. 1 Materials and Methods 1.1 Patient information and observation methods: 21 cases of non-insulin dependent DN patients (according to WHO standard diagnosis and classification), 11 males and 10 females, aged 48.7 ± 7.4 years, duration of 5.7 ± 1.2 years, of which 9 cases of high blood pressure, renal insufficiency in 11 cases. All patients were given oral hypoglycemic agents or insulin to make the normal fasting blood glucose control, plus benazepril (10mg / mg, 1 / day), and even for 2 weeks, and before treatment, normal blood glucose control and benampronate After 2 weeks of treatment, the patients’ blood pressure, 24-hour urinary protein (TUP), urinary albumin clearance (UAER) and creatinine clearance (Ccr) were observed.